Alkermes, Announces Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® 07.08.2025 - 18:04:26 | prnewswire.co.uk Alkermes plc Ireland United Kingdom View original content:https://www.prnewswire.co.uk/news-releases/alkermes-announces-topline-results-from-long-term-open-label-safety-and-durability-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-302025004.html en | boerse | 67983975 |
